News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Scancell Release: Collaboration With ImmuneRegen BioSciences, Inc. (IRBO) Yields Positive Results in Cancer Vaccine Studies


9/7/2010 9:04:13 AM

NOTTINGHAM, England--(BUSINESS WIRE)--Scancell Holdings Plc, (AIM: SCLP), the developer of therapeutic cancer vaccines, announces that a treatment utilising a DNA vaccine based on its ImmunoBody® technology, in combination with ImmuneRegen BioSciences, Inc.®’s lead compound, Homspera®, has significantly improved the immune response of the vaccine in an animal model. Follow-up studies are currently being performed to optimize the effects of Homspera in enhancing the next generation of Scancell’s cancer vaccines.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES